Slide 1: Exchange filing cover letter: Q4 FY2024 Investors Presentation
28th May, 2024 Corporate Relationship Department Manager – Listing M/s. BSE Ltd M/s. National Stock Exchange of India Ltd Dalal Street, Fort “Exchange Plaza”, Bandra – Kurla Complex Mumbai- 400 001 Bandra (E) Mumbai -400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: - Q4 FY2024
Slide 2: Earnings Presentation Q4FY24 & FY24
Earnings Presentation Q4FY24 & FY24
Slide 3: Disclaimer
Disclaimer THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background information about the
Slide 4: Table of Contents
Table of Contents 1 Q4FY24 & FY24 Key Business & Financial Highlights 2 Financial Summary 3 Product Portfolio & Pipeline Natco Pharma Limited – Earnings Presentation – Q4FY24 & FY24
Slide 5: Q4FY24 & FY24 Key Business & Financial Highlights
1 Q4FY24 & FY24 Key Business & Financial Highlights Natco Pharma Limited – Earnings Presentation – Q4FY24 & FY24
Slide 6: Q4FY24 & FY24 – Key Business & Financial Highlights
Q4FY24 & FY24 – Key Business & Financial Highlights Q4FY24: Total Revenue stood at INR 11,103 mn| Pharma Export Formulations at INR 9,549 mn | Consolidated Total Revenue for FY24 stood at INR 41,269 mn Earnings Before Interest Tax Depreciation and Amortization stood at INR 5,393 mn for Q4FY24 and IN
Slide 7: Q4FY24 & FY24 – Quarterly Performance
Q4FY24 & FY24 – Quarterly Performance Revenue Breakup (INR mn) Revenue Breakup (%) – Q4FY24 4% 5% Revenue Division Q4FY24 Q4FY23 Q3FY24 FY24 FY23 5% API Revenue 500 728 463 2,492 2,103 Formulation Formulation – Exports (incl profit share, license income, export service income & 9,549 7,092 6,056 32,
Slide 8: Financial Summary
2 Financial Summary Natco Pharma Limited – Earnings Presentation – Q4FY24 & FY24
Slide 9: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit & Loss Statement (INR Million) Q4FY24 Q4FY23 Q3FY24 FY24 FY23 Total Revenue 11,103 9,269 7,956 41,269 28,117 Total Expenses (before finance cost and depreciation) 5,710 5,588 4,905 22474 17,715 Earnings before interest, tax, depreciation and amortization 5
Slide 10: Key Product Pipeline
3 Key Product Pipeline Natco Pharma Limited – Earnings Presentation – Q4FY24 & FY24
Slide 11: Key Product Pipeline - USA
Key Product Pipeline - USA 24 Para IVs in the pipeline 15 Approved (either tentative or fully) Key Solo FTFs (Para IV) in the pipeline Key Para IV products in the pipeline Therapeutic Therapeutic Key Brand Molecule Key Brand Molecule Segment / Primary Indication Segment / Primary Indication Tracleer
Slide 12: Earnings Call Details – Q4FY24
Earnings Call Details – Q4FY24 The Earnings call to discuss the operational and financial performance of the company with Mr. Rajeev Nannapaneni, Director and Chief Executive Officer and Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences will be held at 11 AM on (Tuesday) 28.05.2024
Slide 13: Thank You
Thank You Contact: Rajeev Menon – Investor Relations Rajesh Chebiyam – EVP, Crop Health Sciences r.menon@natcopharma.co.in / Rajesh.Chebiyam@natcopharma.co.in 040-23546564 https://twitter.com/pharma_natco https://www.linkedin.com/company/natcopharma